Cardiovascular and metabolic risks of untreated apnoea

Obstructive sleep apnoea is often framed as a sleep-quality problem: you snore, you are tired, you use CPAP, problem solved. That framing misses the larger point. Untreated moderate-to-severe apnoea is a cardiometabolic condition that materially increases risk of heart attack, stroke, atrial fibrillation, treatment-resistant hypertension, and type 2 diabetes. The daytime sleepiness is the least of it. This article lays out the cardiovascular and metabolic evidence and what treating apnoea changes.

The mechanisms

Each apnoea event produces a cascade of physiological consequences. Oxygen saturation drops. Carbon dioxide rises. The sympathetic nervous system activates sharply. Blood pressure spikes. Intrathoracic pressure swings. Heart rate surges on arousal. These events repeat dozens to hundreds of times per night in untreated patients.

Cumulatively, this produces:

- Chronic sympathetic nervous system overactivation (daytime blood pressure and heart rate elevated beyond what short-term stress alone explains) - Endothelial dysfunction (the early cellular step toward atherosclerosis) - Inflammation (elevated CRP, IL-6, TNF-alpha) - Oxidative stress (free radical load elevated) - Insulin resistance (cellular response to insulin diminished, glucose handling impaired) - Altered autonomic tone during the day, not just at night

Over years, these mechanisms translate into measurable disease.

The cardiovascular evidence

Hypertension. Moderate-to-severe apnoea is associated with approximately 2 to 3 times the prevalence of hypertension versus controls. Treatment-resistant hypertension (needing 3 or more medications) is strongly associated with untreated apnoea; up to 80 percent of resistant hypertensive patients have significant apnoea. Treating the apnoea reduces blood pressure by 5 to 15 mmHg in most such patients.

Atrial fibrillation. Apnoea approximately doubles AF incidence. Recurrent AF after cardioversion or ablation is much higher in patients with untreated apnoea. Treating apnoea reduces AF burden and improves ablation success.

Coronary disease. Meta-analyses show 30 to 70 percent increased relative risk of myocardial infarction in untreated moderate-to-severe apnoea. Absolute risk increase depends on baseline risk; in a 55-year-old man with moderate cardiovascular risk, untreated apnoea meaningfully raises the 10-year event probability.

Stroke. Approximately 2 to 3 times increased stroke risk in moderate-to-severe apnoea. Sleep apnoea is prevalent in stroke survivors (50 to 70 percent of patients post-stroke have significant apnoea). Treating apnoea after stroke reduces recurrence.

Heart failure. Apnoea is common in heart failure (50 to 70 percent of patients have either obstructive or central apnoea). Treating the apnoea improves left ventricular function and exercise capacity.

Sudden cardiac death. Observational studies show increased sudden cardiac death risk during the overnight period in patients with untreated apnoea, particularly between 2 and 6 am.

The metabolic evidence

Insulin resistance and type 2 diabetes. Apnoea worsens insulin sensitivity independent of obesity. Prevalence of type 2 diabetes in moderate-to-severe apnoea is approximately 2 times higher than BMI-matched controls. Treating apnoea modestly improves glycaemic control.

Metabolic syndrome. Prevalence of metabolic syndrome in untreated apnoea is approximately 50 to 70 percent versus 20 to 30 percent in matched controls.

Weight gain. Apnoea and weight reinforce each other. Apnoea worsens metabolic regulation, reduces daytime activity through fatigue, disrupts appetite hormones. Weight gain worsens apnoea. Treating apnoea often makes weight loss attempts more effective.

Fatty liver disease. Non-alcoholic fatty liver disease is more common in untreated apnoea, likely through combined insulin resistance, inflammation, and hypoxia effects.

What treatment actually changes

Effective treatment (CPAP in most cases, alternative modalities where appropriate) produces:

- Blood pressure reduction of 2 to 10 mmHg systolic on average, more in treatment-resistant patients - Reduction in atrial fibrillation burden - Reduced recurrence of AF post-ablation - Modest improvement in insulin sensitivity - Improved left ventricular function in heart failure - Lower stroke risk (prospective data showing reduction with treatment) - Possibly reduced cardiovascular event rates over years (the evidence here is still maturing; SAVE and RICCADSA trials showed mixed results but adherence was variable) - Improved mortality in severe apnoea (observational data)

The cardiovascular and metabolic benefits are largest in patients with the worst apnoea (AHI over 30), longest treatment adherence, and best CPAP use (4+ hours per night on at least 70 percent of nights).

What this means for specific patients

Patients with treatment-resistant hypertension. Apnoea assessment should be default, not optional. Treatment often improves blood pressure control substantially.

Patients with atrial fibrillation. Particularly recurrent AF after ablation or cardioversion, apnoea assessment is worthwhile. Treating identified apnoea reduces recurrence.

Patients with type 2 diabetes and poor glycaemic control. Apnoea screening is reasonable; treatment is an adjunct to usual diabetes management.

Patients on TRT. TRT can worsen apnoea; screening before and during treatment is standard at our clinic.

Post-stroke patients. Apnoea screening is strongly indicated. NHS stroke services increasingly do this routinely; private patients should too.

Patients with heart failure. Apnoea is common and treatable. Improved cardiac function with treatment is documented.

How we approach cardiovascular integration

A sleep assessment at LoveMyLife routinely includes cardiovascular risk context: baseline blood pressure, lipids, HbA1c, fasting glucose where indicated. Where cardiovascular risk is elevated or cardiovascular disease is present, the sleep assessment is integrated with our cardiovascular prevention service rather than treated as a silo.

Patients identified with significant apnoea on initial assessment are offered prompt treatment with follow-up confirmation that the apnoea is controlled (repeat WatchPAT at 6 to 8 weeks on treatment).

When cardiovascular concern should prompt apnoea assessment

Everyone with:

- Poorly controlled hypertension on appropriate medication - New atrial fibrillation under age 60 - Atrial fibrillation with any recurrence after ablation - Type 2 diabetes with elevated HbA1c despite appropriate management - Heart failure of any cause - Stroke or TIA - Unusual nocturnal symptoms (nocturia, morning headache, unexplained dyspnoea at rest) - Any safety-critical occupation

Apnoea prevalence in these groups is high enough that screening is worthwhile even without classical sleep symptoms.

What we are not claiming

Treating apnoea does not cure cardiovascular disease. It reduces risk. It is one of several interventions alongside lipid management, blood pressure control, diabetes management, lifestyle intervention, and specific cardiovascular medications.

The benefit of treating apnoea is larger in high-risk patients. In low-risk patients with mild apnoea and no symptoms, the cardiovascular benefit of treatment is modest and the decision about CPAP versus alternatives is driven by other factors.

The honest bottom line

Untreated moderate-to-severe obstructive sleep apnoea is a cardiometabolic risk factor, not just a sleep problem. Treating it effectively reduces cardiovascular and metabolic risks meaningfully over years. For patients with cardiovascular disease or significant risk, apnoea assessment is part of sensible prevention.

Ready to start?

If this article has made you think our assessment might help, the next step is a short consultation with one of our sleep-medicine doctors.

Begin your consultation at this link. Online with a WatchPAT One home study, or in person at Westfield London.